PD1 and/or LAG3 binders
The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
1. A LAG3 binder comprising an immunoglobulin single variable domain (ISVD) that binds to LAG3 comprising
a CDR1 comprising the amino acid sequence GRTFSDYVMG (SEQ ID NO: 65) or DYVMG (amino acids 6-10 of SEQ ID NO: 65);
a CDR2 comprising the amino acid sequence AISESGGRTHYADSVKG (SEQ ID NO: 66) or AISESGGRTH (amino acids 1-10 of SEQ ID NO: 66); and
a CDR3 comprising the amino acid sequence TLLWWTSEYAPIKANDYDY (SEQ ID NO: 67); wherein the LAG3 binder binds human LAG3 and wherein the ISVD further comprises a substitution of the amino acids at positions 11 and 89 with amino acids V and L, respectively, wherein the numbering is according to Kabat.
2. The LAG3 binder of claim 1 wherein the ISVD comprises the amino acid sequence:
EVOLVE SGGGVVQPGG SLRLSCAASG RTFSDYVMGW FRQAPGKERE FVAAISESGG RTHYADSVKG RFTISRDNSK NTLYLOMNSL RPEDTALYYC ATTLLWWTSE YAPIKANDYD YWGQGTLVTV SS (SEQ ID NO: 64); or SEQ ID NO: 64 comprising a E1D mutation.
3. The LAG3 binder of claim 1 , wherein the LAG3 binder is linked to an albumin binder comprising an ISVD that binds human albumin.
4. The LAG3 binder of claim 3 wherein the linked albumin binder has a C-terminal extender comprising alanine.
5. An injection device that comprises the LAG3 binder of claim 1 optionally in association with a further therapeutic agent.
6. A vessel that comprises the LAG3 binder of claim 1 optionally in association with a further therapeutic agent.
7. A composition comprising the binder of claim 1 and at least one pharmaceutically acceptable carrier, diluent or excipient.